title: Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.
abstract: OBJECTIVE
  As part of a long-term, relapse-prevention study of antidepressant versus mood stabilizer monotherapy of bipolar II major depressive episode, we prospectively examined the efficacy and mood conversion rate of initial fluoxetine monotherapy. We hypothesized that there would be a statistically significant reduction in depressive symptoms without a clinically meaningful increase in mood conversion symptoms.
  
  
  METHODS
  Patients received open-label fluoxetine monotherapy 10 to 80 mg daily for up to 14 weeks. Primary outcome was change over time in Hamilton Depression Rating score, with secondary outcomes including the proportion of treatment responders and remitters, change over time in Young Mania Rating Scale (YMRS) score, and frequency of mood conversion episodes.
  
  
  RESULTS
  One hundred forty-eight patients had at least 1 post-baseline measurement. Mean Hamilton Depression Rating score decreased by 9.0 points (P < 0.0005). There were 88 responder patients (59.5%; 95% confidence interval [CI], 51.1%-67.4%) (P < 0.0005) and 86 remitter patients (58.1%; 95% CI, 49.7%-66.2%) (P < 0.0005). Mean time to remission was 64.4 days (95% CI, 59.1-69.7 days). Six patients (4.1%; 95% CI, 1.5%-8.6%) (P < 0.0005) had hypomania, and 29 patients (19.6%; 95% CI, 13.5%-26.9%) (P < 0.0005) had subsyndromal hypomania, which did not result in treatment discontinuation. Six patients (4.1%; 95% CI, 1.5%-8.6%) had a YMRS score of 8 or greater (P < 0.0005), and 4 patients (2.7%; 95% CI, 0.7%-6.8%) (P < 0.0005) had a YMRS score of 12 or greater at any study visit.
  
  
  CONCLUSIONS
  Although design limitations constrain the interpretation of the current findings, fluoxetine monotherapy may be an effective short-term treatment of bipolar II major depressive episode with a relatively low rate of syndromal hypomanic episodes.
authors.affiliation: Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. jamsterd@mail.med.upenn.edu
authors.forename: Jay D
authors.initials: JD
authors.lastname: Amsterdam
authors.forename: Justine
authors.initials: J
authors.lastname: Shults
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects*; D000368:Aged; D000369:Aged, 80 and over; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005473:Fluoxetine
references.citation: J Clin Psychiatry. 2001 Aug;62(8):612-6
references.pmid: 11561933
references.citation: J Clin Psychiatry. 2001 Dec;62(12):985-90
references.pmid: 11780881
references.citation: Am J Psychiatry. 1998 Sep;155(9):1247-53
references.pmid: 9734550
references.citation: J Affect Disord. 2005 Feb;84(2-3):209-17
references.pmid: 15708418
references.citation: J Affect Disord. 2005 May;86(1):1-10
references.pmid: 15820265
references.citation: J Clin Psychiatry. 1996;57 Suppl 12A:3-88
references.pmid: 8946806
references.citation: J Clin Psychiatry. 2000 Oct;61(10):804-8; quiz 809
references.pmid: 11078046
references.citation: J Clin Psychopharmacol. 1991 Feb;11(1):52-4
references.pmid: 2040716
references.citation: Bipolar Disord. 2003 Oct;5(5):310-9
references.pmid: 14525551
references.citation: Bipolar Disord. 2004 Feb;6(1):75-81
references.pmid: 14996144
references.citation: Int Clin Psychopharmacol. 2005 Sep;20(5):257-64
references.pmid: 16096516
references.citation: J Clin Psychopharmacol. 1998 Dec;18(6):435-40
references.pmid: 9864074
references.citation: N Engl J Med. 2007 Apr 26;356(17):1711-22
references.pmid: 17392295
references.citation: Int Clin Psychopharmacol. 1989 Oct;4(4):313-22
references.pmid: 2607128
references.citation: Am J Psychiatry. 2006 Feb;163(2):232-9
references.pmid: 16449476
references.citation: Bipolar Disord. 2003 Dec;5(6):421-33
references.pmid: 14636365
references.citation: J Clin Psychiatry. 1994 Sep;55(9):391-3
references.pmid: 7929019
references.citation: Arch Gen Psychiatry. 1988 Aug;45(8):742-7
references.pmid: 3395203
references.citation: J Clin Psychiatry. 2007 Oct;68(10):1472-9
references.pmid: 17960960
references.citation: Acta Psychiatr Scand. 2008 Nov;118(5):347-56
references.pmid: 18727689
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2):171-81
references.pmid: 18344727
references.citation: Br J Psychiatry. 1978 Nov;133:429-35
references.pmid: 728692
references.citation: Am J Psychiatry. 1994 Dec;151(12 Suppl):1-36
references.pmid: 7977902
references.citation: Bipolar Disord. 2003 Dec;5(6):407-20
references.pmid: 14636364
references.citation: J Affect Disord. 2009 Jan;112(1-3):219-30
references.pmid: 18486235
references.citation: Arch Gen Psychiatry. 1998 Jan;55(1):23-5
references.pmid: 9435756
references.citation: Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50
references.pmid: 11958165
references.citation: Biol Psychiatry. 2000 Sep 15;48(6):558-72
references.pmid: 11018227
references.citation: Can J Psychiatry. 1997 Aug;42 Suppl 2:87S-91S
references.pmid: 9288441